Vascular Access Device ComplicationsNCT06547294
Does a Novel Needle Over Catheter Device Improve First Pass Success and Decrease Complications
A study testing Osprey IV in people with Vascular Access Device Complications and Catheterization, Peripheral, run by Community Medical Center, Toms River, NJ at 1 site in United States.
Trial summary
Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Vascular Access Device Complications, Catheterization, Peripheral
- What is being tested?
- Osprey IV
- Type of treatment
- Injection or infusion, Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 0 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2025to Sep 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
None listed.
Who cannot join
- Any gender, < 18 years old.
- Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);
- Previous venous grafts or surgery at the target vessel access site;
- Currently involved in other investigational clinical trials (unless permission is granted by other study Pl)
- Subjects who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating
Trial locations and contacts
1 site in 1 country.
United States1 site
Robert Wood Johnson Barnabas Health Community Medical Center
Toms River, New Jersey, 08755
About this study
Official title: Procedural and Post-Procedural Clinical Performance of a Novel Peripheral Intravenous Needle Over Catheter Device (OspreyTM)
Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. A standardized data entry sheet will be collected at time of enrollment, and then daily thereafter while the subject has the IV. The data collected will remain anonymous.
Read the detailed description
Identification of Subjects:
The emergency department is a designated participating unit providing subjects with medical care that are anticipated to be placed in the observation unit or admitted to an inpatient unit. Subjects who meet inclusion criteria will be consented to be included in the study.
Assignment of Subject Identification Number:
A unique identification number will be given to study subjects. Subject numbers will be assigned in sequential order. The subject number will consist of 6 characters. The first three characters will designate the manufacturer-specific protocol number (SVI). The last three characters will designate the subject by number in sequential order.
Informed Consent:
The nurse trained in placing this device will first consent the patient with written forms provided. All protocol nurses trained in this device will also have completed CITI training courses per our institutional guidelines.
Treatment Assignment:
Within this single arm study, subjects will be assigned to the study in a single treatment group. All patients in the convenience sample who would have received a standard stocked intravenous catheter will instead receive an Osprey catheter provided by the manufacturer. They will be compared against historical controls. Historical controls will be collected from a review of relevant literature, which has been determined to be stable across time and region.
Data Collection Method A Case Report Form (CRF) will be utilized to collect insertion related study data. The CRF will not include any patient identifying information such as name or medical identification number. The subject's demographic (age, race, and gender); baseline information (comorbidities); type of medications/fluids delivered will be documented from already captured Epic documentation.
A second Case Report Form (CRF) will be utilized to collect device performance study data. The CRF will not include any patient identifying information such as name or medical identification number. Device condition (ability to flush and obtain a blood return), Site condition (presence of redness, edema, drainage), patient response (level of pain) and dwell time will be extracted from Epic as this is the current standard practice to do so.
Active patients in the study will be maintained in a file on a secure drive that study personnel have to refer to to follow up active patients. Once active patients are no longer being followed daily, their name will be removed from that file. CRF forms will be filled out by hand and secured in a locked box. The data from both CRFs will be transcribed into a digital worksheet i.e. Microsoft Excel, which will be stored on a secured network drive maintained by the hospital.
Study Procedure Subjects will be admitted into the study according to the aforementioned criteria.
Hospital protocols will be followed for placement of the PIV. The site will be marked with date, time and initials of inserter. During and immediately after the IV placement procedure, the CRF will be initiated by staff associated with this study. If unsuccessful with first attempt at PIV placement, an attempt at another site with the same technique and device will be performed. This will be repeated according to facility policy and procedure until a successful PIV is in place or the physician decides to use an alternative therapy that no longer requires peripheral access. All catheters will be stabilized using the same form of stabilization device for uniformity in securement procedure throughout the duration of the study.
Daily assessments will occur per facility policy and procedure. An assessment will include; any level of pain and/or tenderness; presence of erythema; edema; induration; leakage of fluid or purulent drainage from the puncture site; catheter dysfunction (eg, resistance when flushing, absence of a blood return. Daily assessment will continue until the device is removed, completion of therapy or discharge. Once all the required data is collected, all de-identified data will be entered as a "data set" into the post procedure CRF for management/analysis. The final paper CRF will be placed in a study folder and maintained for record keeping and data analysis.
- Being tested
- Osprey IV, Historical Controls
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Osprey IVDevice
Utilization of novel needle over catheter commercial insertion device
Historical ControlsOther
Outcome rates from catheter over needle devices (traditional manner of inserting peripheral IV)
| Study group | Role | What they receive |
|---|---|---|
| Osprey IV | Experimental | Subjects enrolled will receive the study device as part of their routine medical care. Receives: Device: Osprey IV; Other: Historical Controls |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Attempts
The number of attempts that operator needs to access vein and secure device for proper bidirectional flow
Measured: 10 minutes
Secondary outcomes (9)
Blood culture contamination rates
Proportion of blood culture specimens (when drawn) that are reported with contaminants
Measured: 1 week
Flushing characteristic
whether operator finds flow into patient to be impeded or unimpeded
Measured: 10 minutes
Patient discomfort
Patient's self assessment of level of pain experienced by insertion
Measured: 10 minutes
Time to removal
Total days device remained in place
Measured: 1 week
Removal reason
If removed for device failure vs cessation of therapy
Measured: 1 week
Edema
Presence of edema
Measured: 1 week
Redness
Presence of redness
Measured: 1 week
Drainage
Presence of drainage
Measured: 1 week
Site Pain
Presence of site pain
Measured: 1 week
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Aug 2024
- Study startFeb 2025 (estimated)
- Primary completionApr 2025 (estimated)
- Study completionSep 2025 (estimated)
Why it stopped: Device manufacturer withdrew support
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Vascular Access Device ComplicationsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Single arm with historical controls
- Masking
- None (open label)
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Community Medical Center, Toms River, NJ
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Gerado Chiricolo, MD, Principal investigator, Robert Wood Johnson Barnabas Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06547294
- Sponsor's protocol ID
- Pro2024001057
- Status last verified
- Oct 2026
- First submitted
- 7 Aug 2024
- Last updated
- 22 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Procedural and Post-Procedural Clinical Performance of a Novel Peripheral Intravenous Needle Over Catheter Device (OspreyTM)
- ClinicalTrials.gov ID
- NCT06547294
- Acronym / sponsor ID
- Pro2024001057
- Study type
- Interventional
- Recruitment status
- WithdrawnReason stopped: Device manufacturer withdrew support
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Community Medical Center, Toms River, NJUniversity, hospital or other
- Study start
- Feb 2025 (estimated)
- Primary completion
- Apr 2025 (estimated)
- Study completion
- Sep 2025 (estimated)
- First posted
- 9 Aug 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Emergency Department Patients who were to get intravenous (IV) access through routine medical care will receive it through trademarked catheter via convenience sample. Patient and clinician experience, including adverse events, will be recorded. A standardized data entry sheet will be collected at time of enrollment, and then daily thereafter while the subject has the IV. The data collected will remain anonymous.
Detailed description
Identification of Subjects:
The emergency department is a designated participating unit providing subjects with medical care that are anticipated to be placed in the observation unit or admitted to an inpatient unit. Subjects who meet inclusion criteria will be consented to be included in the study.
Assignment of Subject Identification Number:
A unique identification number will be given to study subjects. Subject numbers will be assigned in sequential order. The subject number will consist of 6 characters. The first three characters will designate the manufacturer-specific protocol number (SVI). The last three characters will designate the subject by number in sequential order.
Informed Consent:
The nurse trained in placing this device will first consent the patient with written forms provided. All protocol nurses trained in this device will also have completed CITI training courses per our institutional guidelines.
Treatment Assignment:
Within this single arm study, subjects will be assigned to the study in a single treatment group. All patients in the convenience sample who would have received a standard stocked intravenous catheter will instead receive an Osprey catheter provided by the manufacturer. They will be compared against historical controls. Historical controls will be collected from a review of relevant literature, which has been determined to be stable across time and region.
Data Collection Method A Case Report Form (CRF) will be utilized to collect insertion related study data. The CRF will not include any patient identifying information such as name or medical identification number. The subject's demographic (age, race, and gender); baseline information (comorbidities); type of medications/fluids delivered will be documented from already captured Epic documentation.
A second Case Report Form (CRF) will be utilized to collect device performance study data. The CRF will not include any patient identifying information such as name or medical identification number. Device condition (ability to flush and obtain a blood return), Site condition (presence of redness, edema, drainage), patient response (level of pain) and dwell time will be extracted from Epic as this is the current standard practice to do so.
Active patients in the study will be maintained in a file on a secure drive that study personnel have to refer to to follow up active patients. Once active patients are no longer being followed daily, their name will be removed from that file. CRF forms will be filled out by hand and secured in a locked box. The data from both CRFs will be transcribed into a digital worksheet i.e. Microsoft Excel, which will be stored on a secured network drive maintained by the hospital.
Study Procedure Subjects will be admitted into the study according to the aforementioned criteria.
Hospital protocols will be followed for placement of the PIV. The site will be marked with date, time and initials of inserter. During and immediately after the IV placement procedure, the CRF will be initiated by staff associated with this study. If unsuccessful with first attempt at PIV placement, an attempt at another site with the same technique and device will be performed. This will be repeated according to facility policy and procedure until a successful PIV is in place or the physician decides to use an alternative therapy that no longer requires peripheral access. All catheters will be stabilized using the same form of stabilization device for uniformity in securement procedure throughout the duration of the study.
Daily assessments will occur per facility policy and procedure. An assessment will include; any level of pain and/or tenderness; presence of erythema; edema; induration; leakage of fluid or purulent drainage from the puncture site; catheter dysfunction (eg, resistance when flushing, absence of a blood return. Daily assessment will continue until the device is removed, completion of therapy or discharge. Once all the required data is collected, all de-identified data will be entered as a "data set" into the post procedure CRF for management/analysis. The final paper CRF will be placed in a study folder and maintained for record keeping and data analysis.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Single arm with historical controls
| Arm | Type | Receives |
|---|---|---|
| Osprey IV | Experimental | Device: Osprey IV, Other: Historical ControlsSubjects enrolled will receive the study device as part of their routine medical care. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (0 listed)
Key exclusion criteria (5 listed)
- Any gender, < 18 years old.
- Requirement for emergent IV placement (patient's condition would be compromised if there is a delay in IV placement);
- Previous venous grafts or surgery at the target vessel access site;
- Currently involved in other investigational clinical trials (unless permission is granted by other study Pl)
- Subjects who are pregnant, planning to become pregnant within 3 months of the procedure, or lactating
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Osprey IVUtilization of novel needle over catheter commercial insertion device | Device | Osprey IV |
| Historical ControlsOutcome rates from catheter over needle devices (traditional manner of inserting peripheral IV) | Other | Osprey IV |
Primary outcome
Number of Attempts
Time frame: 10 minutes
The number of attempts that operator needs to access vein and secure device for proper bidirectional flow
9 secondary outcomes
Blood culture contamination rates
Time frame: 1 week
Flushing characteristic
Time frame: 10 minutes
Patient discomfort
Time frame: 10 minutes
Time to removal
Time frame: 1 week
Removal reason
Time frame: 1 week
Edema
Time frame: 1 week
Redness
Time frame: 1 week
Drainage
Time frame: 1 week
Site Pain
Time frame: 1 week
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Device White PaperLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for Vascular Access Device Complications
Not yet recruiting
Impact of a Long Peripheral Venous Catheter Protocol in Pediatric and Neonatal Care
Vascular Access Devices, Vascular Access
Active, not recruiting
Effectiveness of a Needle-free Connector With Anti-reflux Technology in Reducing Complications From Long Peripheral Venous Catheters in Hospitalised Adult Patients: Randomised Clinical Trial
Vascular Access Devices, Catheters
Not yet recruiting
Reduction of Complications Associated With Extraluminal PICC Management.
Treatment (ProudMe), Vascular Access
Not yet recruiting
Comparing Suture vs. Combined Closure Strategies for Large Blood Vessel Access in Patients Undergoing Transcatheter Aortic Valve Implantation (TAVI)
Aortic Valve Stenosis, Postoperative Complications
Not yet recruiting
The IVCare Adaptive Platform Trial
Device Related Infection, Vascular Access Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gerado Chiricolo, MD principal investigator
Robert Wood Johnson Barnabas Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Osprey IV in people with Vascular Access Device Complications and Catheterization, Peripheral, run by Community Medical Center, Toms River, NJ at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 0 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Attempts (time frame: 10 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.